articleThe Lancet OncologyMar 23, 2015Closed access

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

JSJeffrey S. WeberSPSandra P. D’AngeloDRDavid R. MinorFSF. Stephen HodiRGRalf Gutzmer

Moffitt Cancer Center · Memorial Sloan Kettering Cancer Center · +30 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

2,661
total citations
FWCI
168.09
Percentile
100%
References
36
Citations per year

Authors

28

Topics & keywords

Topics
Keywords
  • Open label
  • Medicine
  • Nivolumab
  • Oncology
  • Chemotherapy
  • Internal medicine
  • Ipilimumab
  • Randomized controlled trial
No related works found for this paper.

Funding